---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017049"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2026-05-14T20:09:02+00:00"
generated_at: "2026-05-14T20:57:54.576343+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M

## Summary
- Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.
- Product sales $10.4M, up 28.4% YoY; gross margin 45.0% vs 41.6%.
- Cash position $6.8M at Mar 31, 2026, up from $3.8M; generated $3.4M free cash flow in Q1.
- Settled all disputes with former contract manufacturer for net $2M payment to ImmuCell, to fund capacity expansion.
- Manufacturing output increased to >450K units/month from ~380K in 2025.

## SEC filing metadata
- accession: 0001437749-26-017049
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2026-05-14T20:09:02+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/0001437749-26-017049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/iccc20260512_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017049
- JSON: https://secwatch.observer/filing/0001437749-26-017049.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017049.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue approximately $10.4 million, net income $1.9 million, EPS $0.21 per basic share.
  - Period: the quarter ended March 31, 2026
  - Revenue: approximately $10.4 million
  - Net income: $1.9 million
  - EPS: $0.21 per basic share
  - Result: reported results
  source text: million compared to the first quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “These results were driven by 28.4% growth in product sales to $10.4 million and an expansion of gross margins to 45.0% that reflects higher volumes, manufacturing efficiencies, and price realization. ImmuCell generated $3.4 million free cash flow in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/0001437749-26-017049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.